The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) co-sponsored this public virtual workshop on August 30, 2022.
The following topics were discussed:
The current state of development of pathogen-directed products used to prevent healthcare-associated infections
Evidence supporting decolonization and pathogen reduction (in colonized patients) as a strategy to prevent infection and transmission of antimicrobial-resistant healthcare-associated pathogens
Antimicrobial resistance threats as potential targets for decolonization and pathogen reduction
Challenges and potential approaches to drug development and registration of products for the prevention of healthcare-associated infections
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
